Annexon, Inc. (NASDAQ:ANNX) Insider Sells 5,521 Shares

Annexon, Inc. (NASDAQ:ANNX) insider Jamie Dananberg sold 5,521 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $2.96, for a total value of $16,342.16. Following the sale, the insider now owns 33,479 shares of the company’s stock, valued at approximately $99,097.84. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Annexon Stock Performance

Shares of NASDAQ ANNX traded down $0.02 during trading on Thursday, hitting $2.83. 796,392 shares of the company were exchanged, compared to its average volume of 1,392,680. Annexon, Inc. has a 12-month low of $2.63 and a 12-month high of $8.40. The company has a fifty day moving average price of $4.33 and a 200-day moving average price of $5.59. The firm has a market capitalization of $301.65 million, a PE ratio of -2.70 and a beta of 1.07.

Hedge Funds Weigh In On Annexon

A number of institutional investors have recently bought and sold shares of ANNX. BNP Paribas Financial Markets purchased a new stake in shares of Annexon in the 4th quarter valued at approximately $59,000. CANADA LIFE ASSURANCE Co purchased a new position in Annexon in the fourth quarter worth approximately $77,000. E Fund Management Co. Ltd. grew its position in Annexon by 36.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after acquiring an additional 4,086 shares during the period. Forefront Analytics LLC increased its stake in Annexon by 56.8% during the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock worth $84,000 after acquiring an additional 5,950 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in Annexon in the fourth quarter valued at $98,000.

Wall Street Analyst Weigh In

Several analysts recently commented on ANNX shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Annexon in a report on Tuesday, December 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of Annexon in a research note on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.